


O I P INFORMATION DISCLOSURE CITATION <small>(Use several sheets if necessary)</small> MAY 10 2001				ATTY DOCKET NO. 13105	SERIAL NO. 09/692,077	
				FILING October 19, 2000	GROUP 1614	
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DWJ	5,648,482	07/15/97	Meyer	536	24.33	—
	5,846,710	12/08/98	Bajaj	435	6	—
	5,865,092	01/05/99	Dale et al.	435	6	—
	5,888,819	03/30/99	Goelet et al.	435	5	—
	5,981,174	11/09/99	Wolf et al.	435	6	—
	6,004,744	12/21/99	Goelet et al.	435	5	—
	6,013,431	01/11/00	Soderlund et al.	435	5	—
DWJ	6,156,503	12/05/00	Drazen et al.	435	6	—
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
			Limbird, L. E. (1988) FASEB J 2, 2686-2695			
			Eason, M. G. and Liggett, S. B. (1993) Mol.Pharmacol. 44, 70-75			
EXAMINER			DATE CONSIDERED			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE CITATION

MAY 10 2001

(use several sheets if necessary)

Docket Number (Optional) 13105	Application Number 09/692,077
Applicant(s) Liggett et al.	
Filing Date October 19, 2000	Group Art Unit 1614

EXAMINER
INITIALS

TRADEMARK OFFICE OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

DDJ	Handy, D. E., Flordellis, C. S., Bogdanova, N. N., Bresnahan, M. R., and Gavras, H. (1993) Hypertension 21, 861-865
	Tavares, A., Handy, D. E., Bogdanova, N. N., Rosene, D. L., and Gavras, H. (1996) Hypertension 27, 449-455
	Hein, L., Limbird, L. E., Eglen, R. M., and Kobilka, B. K. (1999) Ann NY Acad Sci 881, 265-271
	Rohrer, D. K. and Kobilka, B. K. (1998) Physiol Rev 78, 35-52
	Ruffolo, R. R., Jr., Nichols, A. J., Stadel, J. M., and Hieble, J. P. (1993) Annu Rev Pharmacol Toxicol 32, 243-279
	Sallinen, J., Haapalinna, A., Viitamaa, T., Kobilka, B. K., and Scheinin, M. (1998) The Journal of Neuroscience 18, 3035-3042
	Sallinen, J., Haapalinna, A., Macdonald, E., Viitamaa, T., Lahdesmaki, J., Rybnikova, E., Pelto-Huikko, M., Kobilka, B. K., and Scheinin, M. (1999) Mol Psychiatry 4, 443-452
	Altman, J. D., Trendelenburg, A. U., MacMillan, L., Bernstein, D., Limbird, L., Starke, K., Kobilka, B. K., and Hein, L. (1999) Mol Pharmacol. 56, 154-161
	Hein, L., Altman, J. D., and Kobilka, B. K. (1999) Nature 402, 181-184
	Link, R. E., Desai, K., Hein, L., Stevens, M. E., Chruscienski, A., Bernstein, D., Barsh, G. S., and Kobilka, B. K. (1996) Science 273, 803-805
	Makaritsis, K. P., Handy, D. E., Johns, C., Kobilka, B., Gavras, I., and Gavras, H. (1999) Hypertension 33, 14-17
DDJ	Liggett, S. B., Ostrowski, J., Chestnut, L. C., Kurose, H., Raymond, J. R., Caron, M. G., and Lefkowitz, R. J. (1992) J.Biol.Chem. 267, 4740-4746

EXAMINER

Diana P.

DATE CONSIDERED

2/26/04

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional) 13105	Application Number 09/692,077
Applicant(s) Liggett et al.	
Filing Date October 19, 2000	Group Art Unit 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>DMS</i>	Eason, M. G., Moreira, S. P., and Liggett, S. B. (1995) J.Biol.Chem. 270, 4681-4688
	Eason, M. G. and Liggett, S. B. (1992) J.Biol.Chem. 267, 25473-25479
	Jewell-Motz, E. A. and Liggett, S. B. (1995) Biochem 34, 11946-11953
	Kurose, H. and Lefkowitz, R. J. (1994) J.Biol.Chem. 269, 10093-10099
	Pitcher, J. A., Freedman, N. J., and Lefkowitz, R. J. (1998) Annu Rev Biochem 67, 692
	Heinonen, P., Koulu, M., Pesonen, U., Karvonen, M. K., Rissanen, A., Laakso, M., Valve, R., Uusitupa, M., and Scheinin, M. (1999) J Clin Endocrinol Metab 84, 2429-2433
	Baldwin, C. T., Schwartz, F., Baima, J., Burzstyn, M., DeStefano, A. L., Gavras, I., Handy, D. E., Joost, O., Martel, T., Manolis, A., Nicolaou, M., Bresnahan, M., Farrer, L., and Gavras, H. (1999) Am J Hypertens 12, 853-857
<i>DMS</i>	Eason, M. G., Jacinto, M. T., and Liggett, S. B. (1994) Mol.Pharmacol. 45, 696-702
	Jewell-Motz, E. A., Small, K. M., and Liggett, S. B. (2000) J.Biol.Chem.
	Small, K. M., Forbes, S. L., Rahman, F. F., Bridges, K. M., and Liggett, S. B. (2000) J.Biol.Chem. 275, 23059-23064
	Hausdorff, W. P., Bouvier, M., O'Dowd, B. F., Irons, G. P., Caron, M. G., and Lefkowitz, R. J. (1989) J.Biol.Chem. 264, 12657-12665
<i>DMS</i>	Baron, B. M. and Siegel, B. W. (1990) Mol Pharmacol 38, 348-356

EXAMINER

Diana P.

DATE CONSIDERED

2/26/04

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p style="text-align: center;">Q1P INFORMATION DISCLOSURE CITATION <small>(use several sheets if necessary)</small></p> <p style="text-align: center;">MAY 10 2001</p> <p style="text-align: center;">RECEIVED PATENT & TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE</p>		Docket Number (Optional) 13105	Application Number 09/692,077
		Applicant(s) Liggett et al.	
		Filing Date October 19, 2000	Group Art Unit 1614
<p>OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i></p> <p>Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. (1985) Anal.Biochem. 150, 76-85</p> <p>Onorato, J. J., Palczewski, K., Regan, J. W., Caron, M. G., Lefkowitz, R. J., and Benovic, J. L. (1991) Biochem 30, 5118-5125</p> <p>Jewell-Motz, E. A. and Liggett, S. B. (1996) J.Biol.Chem. 271, 18082-18087</p> <p>MacMillan, L. B., Hein, L., Smith, M. S., Piascik, M. T., and Limbird, L. E. (1996) Science 273, 801-805</p> <p>Munroe, P. B. and Caulfield, M. J. (2000) Curr Opin Genet Dev 10, 325-329</p> <p>"Introduction to α-adrenoceptors," <i>mrs</i> http://www.adrenoceptor.com/alphaintro.htm (Website visited April 2, 2001)</p> <p>Robinson, E. J. Hudson, A. "Adrenoceptor pharmacology," <i>mrs</i> (author, vol. 1 pp. - N/A) http://www.tocris.com/adrenoceptor.htm, (Website visited March 19, 2001)</p> <p>November 1998 <i>mrs</i> (vol. pp. - N/A)</p>			
EXAMINER <i>Diane B</i>	DATE CONSIDERED 2/24/04		

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

O I P E
MAR 13 2003
PATENT & TRADEMARK OFFICE

FORM PTO - 1449 LIST OF PATENTS AND TRADEMARKS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT								ATTY DOCKET: 10738-43 APPLICANTS: Kersten M. Small et al FILING DATE: October 19, 2000 FOR: ALPHA-2B-ADRENERGIC RECEPTOR POLYMORPHISMS	SERIAL NO. 09/692,077 GROUP: 1634			
UNITED STATES LETTERS PATENT												
Exr. Init.		DOCUMENT NUMBER						DATE	NAME	CLASS	SUB CLASS	
DPS	aa	5	5	9	5	8	8	0	Jan. 21, 1997	Weinshank et al	435	7.21
FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUB CLASS	
DPS	ba	WO	01	2	9	0	8	2	April 26, 2001	PCT		
OTHER ART (INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)												
DPS	ca	HEINONEN P. et al: "Identification of a three-amino acid deletion in the alpha2B-adrenergic receptor that is associated with reduced basal metabolic rate in obese subjects." <i>The Journal of Clinical Endocrinology and Metabolism</i> , United States, July 1999, Vol. 84, No. 7, pages 2429-2433.										
	cb	BALDWIN C.T., et al: "Identification of a polymorphic glutamic acid stretch in the alpha2B-adrenergic receptor and lack of linkage with essential hypertension." <i>American Journal of Hypertension: Journal of the American Society of Hypertension</i> , United States, Sep. 1999, Vol. 12, No. 9, Pt. 1, pages 853-857.										
	cc	JEWELL-MOTZ, E.A. et al: "An acidic motif within the third intracellular loop of the alpha2C2 adrenergic receptor is required for agonist-promoted phosphorylation and desensitization." <i>Biochemistry</i> , United States 19 Sep. 1995, Vol. 34, No. 37, 19 September 1995, pages 11946-11953.										
	cd	COMINGS, D.E., et al: "Additive effect of three noradrenergic genes (ADRA2a, ADRA2C, DBH) on attention-deficit hyperactivity disorder and learning disabilities in Tourette syndrome subjects." <i>Clinical Genetics</i> , Denmark, March 1999, Vol. 55, No. 3, pages 160-172.										
	ce	MAKARITSIS K.P., et al: "Role of the alpha2B-adrenergic receptor in the development of salt-induced hypertension." <i>Hypertension</i> . United States, Jan. 1999, Vol. 33, No. 1, January 1999, pages 14-17.										
	cf	MICHEL M.C., et al: "Functional correlates of alpha(2A)-adrenoceptor gene polymorphism in the HANE study." <i>Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association-European Renal Association</i> . England, Nov. 1999, Vol. 14, No. 11, pages 2657-2663.										
	cg	FREEMAN K., et al: "Genetic polymorphism of the alpha 2-adrenergic receptor is associated with increased platelet aggregation, baroreceptor sensitivity, and salt excretion in normotensive humans." <i>American Journal of Hypertension: Journal of the American Society of Hypertension</i> . United States, Sep. 1995, Vol. 8, No. 9, pages 863-869.										
	ch	SMALL K.M., et al: "Polymorphic deletion of three intracellular acidic residues of the alpha 2B-adrenergic receptor decreases G protein-coupled receptor kinase-mediated phosphorylation and desensitization." <i>The Journal of Biological Chemistry</i> . United States, 16 Feb 2001, Vol. 276, No. 7, pages 4917-4922.										
DPS	ci	SNAPIR A., et al: "An insertion/deletion polymorphism in the alpha2B-adrenergic receptor gene is a novel genetic risk factor for acute coronary events." <i>Journal of the American College of Cardiology</i> . United States, May 2001, Vol. 37, No. 6, pages 1516-1522.										

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and no considered. Include copy of this form with next communication to applicant.

Diana P.S.

2/26/04